Flipped C-Terminal Ends of APOA1 Promote ABCA1-Dependent Cholesterol Efflux by Small HDLs.
Level 5 - mechanism / opinion, no new human data
Mechanistic bench research combining in vitro model systems, molecular dynamics, and ex vivo human plasma assays.
PubMed 38018436 · doi:10.1161/CIRCULATIONAHA.123.065959
What was done
The authors investigated why small high-density lipoprotein (HDL) particles are superior at promoting ABCA1-mediated macrophage cholesterol efflux capacity (CEC). They tested four distinct sizes of reconstituted HDL (rHDL) and analyzed human plasma samples from healthy controls and lecithin-cholesterol acyltransferase (LCAT)-deficient individuals. Methods included macrophage and ABCA1 CEC assays, tandem mass spectrometry of chemically cross-linked peptides, molecular dynamics simulations of apolipoprotein A1 (APOA1) conformation, and in vitro incubation of plasma with recombinant human LCAT.
What was found
In rHDL models, CEC increased progressively as particle size decreased. Mass spectrometry and molecular dynamics simulations showed that the C-terminus of APOA1 had markedly higher mobility and flipped off the lipid surface in the smallest HDL species, whereas on larger particles it adhered to the lipid core as a helical bundle. In human plasma samples, LCAT-deficient subjects maintained normal total CEC despite very low overall HDL particle counts. Isolated extra-small HDL from both LCAT-deficient and control subjects exhibited 3- to 5-fold greater CEC compared to larger HDL subclasses. Exogenous addition of human LCAT to control and LCAT-deficient plasma converted small HDL into larger particles and markedly reduced CEC.
Why it matters
This study identifies a specific structural mechanism—conformational flipping of the APOA1 C-terminus—explaining why small HDL particles drive ABCA1-mediated cholesterol efflux. It provides mechanistic support for evaluating specific HDL particle subpopulations and functional efflux capacity rather than total circulating HDL cholesterol levels when assessing cardiovascular risk.
Limits
Exact participant numbers (sample size) for the control and LCAT-deficient cohorts are not reported in the abstract. Findings are derived from in vitro model systems, molecular simulations, and ex vivo plasma assays, lacking direct longitudinal clinical outcome data.
Cited by
- contradicts Small HDL particles are less capable of clearing LDL particles and facilitating reverse cholesterol transport than larger HDL particles.